

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

INTERVENTIONAL PROCEDURES PROGRAMME

Equality impact assessment

Laparoscopic cryotherapy for renal cancer

The impact on equality has been assessed during guidance development according to the principles of the NICE Equality scheme.

Scoping

- | |
|--|
| 1. Have any potential equality issues been identified during the scoping process (development of the scope or discussion at the Committee meeting), and, if so, what are they? |
|--|

Disability: All individuals with cancer are covered by the Equality Act 2010. Gender: Kidney cancer is more common in men than women. Age: The incidence of kidney cancer begins to rise after the age of 40 and is highest in people older than 65.
--

Ethnicity: In England, kidney cancer is significantly lower in Asian ethnic and the black ethnic group than the white ethnic group for all ages.
--

- | |
|--|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? If there are exclusions listed in the scope (for example, populations, treatments or settings), are these justified? |
|--|

This was not thought to have an impact on the assessment of the procedure. No exclusions were applied.
--

- | |
|--|
| 3. Has any change to the scope (such as additional issues raised during the Committee meeting) been agreed to highlight potential equality issues? |
|--|

No

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

Gender: The majority of patients in all comparative studies were male where gender was reported (58% – 91%, 7 studies).

Age: patients in 6 of the 8 comparative studies reported in the overview had a mean age >65 years.

No specific data relating to disability and ethnicity was identified in the literature presented in the overview.

In addition the following was included in the overview:

Issues for consideration by IPAC

The evidence highlighted that the rare genetic condition von Hippel-Lindau disease is associated with renal cell carcinoma and there was some evidence of this condition in patients treated with this procedure. However, the impact of this information on any guidance produced to the Committee is minimal since (as highlighted in the scope) all individuals with renal cell carcinoma are covered by the equalities legislation. There was no evidence on the use of this procedure in patients with this condition.

2. Have any other potential equality issues been raised in the overview, specialist adviser questionnaires or patient commentary, and, if so, how has the Committee addressed these?

No

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

No

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access a technology or intervention compared with other groups? If so, what are the barriers to access for the specific group?

No

5. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 4, or otherwise fulfil NICE's obligation to promote equality?

Not applicable

6. Have the Committee's considerations of equality issues been described in the consultation document, and, if so, where?

No

Final interventional procedures document

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access a technology or intervention compared with other groups? If so, what are the barriers to access for the specific group?

Not applicable

3. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 2, or otherwise fulfil NICE's obligations to promote equality?

Not applicable

4. Have the Committee's considerations of equality issues been described in the final interventional procedures document, and, if so, where?

No

Approved by Centre or Programme Director (name): Mirella Marlow

Date: 1 June 2011